G1 Therapeutics, Inc. (GTHX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about G1 Therapeutics, Inc. (GTHX)
Go deeper and ask any question about GTHX
Company Performance
Current Price
as of Sep 13, 2024$7.15
P/E Ratio
N/A
Market Cap
$377.22M
Description
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Metrics
Overview
- HQResearch Triangle Park, NC
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerGTHX
- Price$7.15+0.28%
Trading Information
- Market Cap$377.22M
- Float82.02%
- Average Daily Volume (1m)1,582,988
- Average Daily Volume (3m)2,154,576
- EPS-$0.86
Company
- Revenue$58.20M
- Rev Growth (1yr)-60.97%
- Net Income-$5.47M
- Gross Margin95.57%
- EBITDA Margin-20.63%
- EBITDA-$3.41M
- EV$106.81M
- EV/Revenue1.84
- P/EN/A
- P/S6.45
Documents
SEC Filings
Factset Street Account